Actively Recruiting
Improving Patient Assessment After Acute Kidney Injury (AKI)
Led by University of Nottingham · Updated on 2026-05-06
100
Participants Needed
1
Research Sites
189 weeks
Total Duration
On this page
Sponsors
U
University of Nottingham
Lead Sponsor
U
University Hospitals of Derby and Burton NHS Foundation Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are: 1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI? 2. What are the experiences of patients after AKI? 3. What interventions should be recommended to improve assessment and support of patients after AKI? Participants will be asked to do one or more of: * blood tests to measure kidney function in different ways * have measurement of their body composition * complete questionnaires about their symptoms * have an interview with a researcher about their experiences * discussion to develop an action plan based on findings
CONDITIONS
Official Title
Improving Patient Assessment After Acute Kidney Injury (AKI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 85 years
- For observational study: AKI stage 2 or 3 during hospital admission or AKI stage 1 lasting at least 7 days during hospital admission
- 60 to 90 days after peak creatinine
- For qualitative interview study: AKI during hospital admission
- For participatory workshop: relevant experience related to AKI as a patient, carer, professional, or community member
- Ability to give informed consent
- Ability to communicate in English (workshops only)
You will not qualify if you...
- Unable to give informed consent
- No baseline creatinine available in the previous 12 months
- Pregnancy or breastfeeding (observational study only)
- Current dialysis treatment
- Kidney transplant recipient
- Presence of pacemaker (observational study only)
- Previous amputation (observational study only)
- Allergy to Omnipaque contrast agent (observational study only)
- Manifest thyrotoxicosis (observational study only)
- Severe ascites or peripheral oedema lasting more than 1 minute after compression (observational study only)
- Receiving palliative care (qualitative interview study only)
- Unable to communicate in English (workshops only)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals of Derby and Burton NHS Foundation Trust
Derby, Derbyshire, United Kingdom, DE22 3DT
Actively Recruiting
Research Team
K
Kerry Horne Dr, BMBCh
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here